Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Clinical trial NCT04233021 · COMPLETED

Trial details

NCT number: NCT04233021
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer Metastatic Leptomeningeal Metastasis Brain Metastases EGFR Activating Mutation

Start date: 2020-07-16
Primary completion: 2023-03-15
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.